Arctic Bioscience – More than 75% recruited in the phase IIb HeROPA clinical trial
With reference to the Q3 update from November 2nd 2023 which reported more than 50% recruited patients to the phase IIb clinical trial HeROPA, Arctic Bioscience is pleased to report that we have now recruited more than 75% of the patients required for the trial.
The HeROPA phase IIb clinical trial of HRO350 - a novel, oral drug candidate for the treatment of mild-to-moderate psoriasis - is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway. As planned, recruitment speed has increased throughout fall as new clinics have been activated. Recruitment is going particularly well in Germany and Poland.
A total of 519 patients are to be included in the trial. To date, more than 75% of the needed patients have been recruited.
"We are very pleased about the current recruitment speed in our HeROPA clinical trial, which brings us closer to our estimated mid 2024 data read-out." says CEO Christer L. Valderhaug.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.